Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06752616

Acute Agitation in Emergency Psychiatry

The purpose of the study is to improve the pharmacological treatment of psychiatric patients with acute agitation.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–64 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2 / Phase 3

Primary location

Mental Health Center Copenhagen, Bispebjerg

Copenhagen N, 2400, Denmark

Location status: Recruiting

Location contact

Lone Baandrup

CONTACT

[email protected]

0045 91165903

Marie Vang, MD

CONTACT

About this study

The initial treatment of acute agitation aims to reduce suffering, abort the immediate risk of harm to self or others, and prevent the use of coercive measures such a physical and mechanical restraint. With this research project, we aim to build the initial structure of a visionary platform design and to examine the efficacy, tolerability, and safety of two hitherto under-investigated compounds versus the current standard of care for acutely agitated patients when de-escalation techniques have failed. After obtaining the results of the initial phase, we plan to apply for future funding to maintain and expand the platform design with the addition of relevant experimental arms. The proposed platform design aims to anwer the question What is the best treatment for acutely agitated patients in inpatient psychiatric settings?

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 18-64 years
  • Agitation with the need for tranquillization in inpatient psychiatric settings including psychiatric emergency rooms
  • Total score of ≥14 on the PANSS Excited Component (PEC)
  • A score ≥4 on at least 1 of the 5 items of the PEC
  • Informed consent obtained prior to the occurrence of the emergency

Exclusion criteria

  • Involuntary psychiatric admission according to the Danish Mental Health Act
  • Female patients who are breastfeeding
  • Female patients aged <50 years and unable to perform a negative urine screen for pregnancy and not using safe contraceptives
  • Body weight <50 kg
  • Extreme obesity defined as estimated BMI≥ 40 kg/m2
  • Clinical situations where acute administration of an antipsychotic is preferred to treat acute agitation (in the opinion of the investigator)
  • The patient deemed unwilling or unable to cooperate with study procedures (in the opinion of the investigator)
  • Insufficient language skills that interfere with reading, writing, and providing written informed consent in Danish or other available languages (in the opinion of the investigator)
  • Clinical suspicion of contraindications for one of the treatment arms
  • Use of benzodiazepines, other sedatives, or antipsychotic drugs in addition to usual treatment (i.e., additional PN sedative prescriptions) in the 4 hours before study treatment
  • Known allergy to any of the study medications

Treatment and study plan

Sublingual Dexmedetomidine

Drug

Sublingual dexmedetomidine 180 mcg, possible second dose 90 mcg after 2 hrs

Buccal midazolam

Drug

Buccal midazolam 10 mg, possible second dose 10 mg after 2 hrs

Oral lorazepam

Drug

Oral lorazepam 4 mg, possible second dose 4 mg after 2 hrs

Primary outcomes

  1. The Excited Component of the Positive and Negative Syndrome Scale (PEC)

    Time frame: 60 minutes

    The Excited Component of the Positive and Negative Syndrome Scale (PEC) consists of 5 clinician-rated items associated with agitation from the Positive and Negative Syndrome Scale (PANSS). Scores range from 5 to 35. Higher is worse.

Secondary outcomes

  1. PEC score earliest time with difference

    Time frame: 30, 60, 90, and 120 minutes

    The earliest time where a statistically significant difference in agitation is apparent as measured by change from baseline PEC score (change from pre- to post-dose PEC score at 30, 60, 90, and 120 minutes)

  2. Tranquillized or asleep

    Time frame: 30, 60, 90, and 120 minutes post-dose

    Proportion tranquillized or asleep (measured as ≤4 on the BARS**) by 30, 60, 90, and 120 minutes post-dose

  3. Physical restraint

    Time frame: 12 hours post-dose

    Proportion physically restrained from administration to 12 hours post-dose

  4. Mechanical restraint

    Time frame: 12 hours post-dose

    Proportion mechanically restrained from administration to 12 hours post-dose

  5. Rescue medication

    Time frame: 4-12 hours post-dose

    Proportion given rescue medication 4-12 hours post-dose

  6. Patient-reported satisfaction

    Time frame: From 2 to 24 hrs post-dose when the participant is able to cooperate

    Patient-reported satisfaction measured using 4 items from the Treatment Satisfaction Questionnaire for Medication II. Each item is answered on a 7-point Likert scale from 1 (extremely dissatisfied) to 7 (extremely satisfied). Score range is from 4 to 28. Higher is better.

Study contacts

Contact information is provided by the study sponsor or research team.

Lone Baandrup, MD, DMSc

CONTACT

[email protected]

00 45 91165903

Marie Vang Jensen, MD

CONTACT

[email protected]

0045 6199 7358

Sponsors and collaborators

Lead sponsor

Lone Baandrup

Other

Collaborators

  • Capital Region's Pharmacy (Region Hovedstadens Apotek), Marielundvej 25, 2730 Herlev, Denmark
  • University Hospital Bispebjerg and Frederiksberg

Registry information

Official study title

Advancing the Quality of Treatment and Care for Acute Agitation in Emergency Psychiatry

Important dates

Study start
2024
Primary completion
2027
Study completion
2027
First posted
Dec 30, 2024
Registry last updated
Jan 1, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.